We came across a bullish thesis on Compass Therapeutics, Inc. in r/stocks from Cute_Confidence6033. In this article we will summarize the bulls’ thesis on CMPX. Compass Therapeutics, Inc. stock was trading at $5.70 on January 16.
Compass Therapeutics (CMPX) is a clinical-stage oncology company with a portfolio focused on large, underserved cancer markets, and its current valuation appears disconnected from the scale of its opportunity. With a share price of around $6 and a market capitalization of about $1.2 billion, the company maintains a strong cash position of $209 million against a historically manageable annual cash burn of $30 to $50 million, providing a clue through multiple readouts of critical data.
Quality of ownership is a key differentiator, with approximately 65% ​​institutional ownership led by specialist healthcare investors such as Tang Capital, OrbiMed, Suvretta, Vivo, BVF and Patient Square, along with 10% internal ownership and a long-standing board of directors indicating strategic continuity. The primary value driver is CTX-009 (tovecimig), with a Phase 3 program in bile duct cancer targeting a peak sales opportunity estimated at $1.5 billion and a Phase 2 program in colorectal cancer with potential in excess of $2 billion, significantly expanding the targeted patient population.
Additional upside comes from CTX-471 in solid tumors, CTX-8371 in PD-1-resistant tumors, and early-stage PD-1 x VEGF programs, bringing the total pipeline potential above $4.5 billion. Recent developments bolster confidence, including the hiring of Arjun Prasad, a recognized business leader in cholangiocarcinoma, encouraging signs from the Phase 3 COMPANION-002 trial showing fewer deaths than projected, and the appointment of a former Sanofi/Genzyme executive as a senior manager.
With major catalysts ahead, including BTC Phase 3 data in March 2026, ASCO filing in mid-2026, and a potential BLA filing in late 2026, Compass Therapeutics offers highly asymmetric catalyst-driven upside, with bullish scenarios implying substantial revaluation if clinical success is confirmed.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial ramp, its strong net cash position and the advantages of its broader gene editing portfolio. The CRSP share price has appreciated approximately 30.60% since our coverage. while the thesis was being developed. Cute_Confidence6033 shares a similar thesis, but emphasizes the advantages of catalyst-driven late-stage oncology in Compass Therapeutics with multiple binary readouts ahead.